Intragel is developing a gel-based drug delivery system, SRGel, that enables localized, sustained release of anticancer drugs directly into solid tumors, significantly enhancing therapeutic efficacy while minimizing systemic side effects. Their first product, TumoCure, utilizes this platform to deliver high concentrations of cisplatin for the treatment of head and neck cancer, addressing the limited options available for patients with recurrent disease.
Funding
Funding not disclosed
Founders
Product
Problem
Many solid tumors are difficult to treat effectively due to limited drug penetration, rapid systemic drug clearance, and significant off-target toxicities associated with conventional chemotherapy. Patients with inoperable or chemo-resistant tumors often have limited treatment options and poor prognoses.
Solution
Intragel is developing SRGel, a solvent-free, gel-based drug delivery platform for localized and sustained release of anticancer drugs directly into solid tumors. The SRGel platform enables high drug loading and prolonged drug release, maximizing therapeutic efficacy while minimizing systemic exposure and adverse effects. SRGel is administered via direct injection into the tumor, including surgically inaccessible tumors, and releases the drug locally over a period of up to two months. Intragel's lead product, TumoCure, utilizes SRGel to deliver high concentrations of cisplatin for the treatment of head and neck cancer.
Target Audience
Intragel's primary target audience includes oncologists and hospitals treating patients with solid tumors, particularly those with head and neck cancer, who require localized and sustained drug delivery to improve treatment outcomes and reduce side effects.
Features
- Hydrophobic, biocompatible, and biodegradable gel-based composition
- High drug loading capacity (up to 50%)
- Sustained drug release for up to 2 months
- Ready-to-use, pre-filled syringe for easy intratumoral injection
- Localized drug action with minimal systemic toxicity
- Compatible with a wide range of existing anticancer drugs
- Long shelf life of up to 24 months at room temperature